Oct 05, 2023 – A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups are advancing an array of tests to detect diseases sooner and personalize treatments. 

Apr 06, 2023 – Molecular diagnostics company CellMax Life has appointed Stan Lapidus and Ron Andrews to its

Feb 10, 2023 – Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.

Jan 26, 2023 – CellMax Life announced positive results from a multisite U.S. study that showed that its FirstSight blood test is highly accurate in detecting colorectal cancer and advanced adenomas. 

NEW YORK; Jan 19, 2023 – Cancer screening firm CellMax Life shared new data this week from a multi-site prospective study of its blood-based colorectal cancer detection assay, FirstSight.

FDANews; August 30, 2021 – Molecular diagnostics company CellMax Life’s FirstSight pre-cancer and cancer detection blood test has received the FDA’s Breakthrough Device designation.

GenomeWeb; August 27, 2021 – CellMax Life said this week that its FirstSight colorectal precancer and cancer detection blood test has received Breakthrough Device Designation from the US Food and Drug Administration.

Aug. 26, 2021 – The FirstSight blood test is a liquid biopsy, which will help measure colorectal neoplasia associated epithelial cells and DNA markers in human blood

January 15, 2021 – A noninvasive multimodal blood test demonstrated high sensitivity and specificity for the detection of colorectal advanced neoplasia, according to prospective study results presented at Gastrointestinal Cancers Symposium.